Advertisement

Topics

Ixekizumab (Taltz) - Biotech, Pharma and Life Science Channel

22:14 EST 16th January 2019 | BioPortfolio

Ixekizumab (Taltz) is a humanised IgG4 monoclonal antibody that selectively binds with high affinity to the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.iii IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses, and elevated levels of IL-17A have been implicated in the pathogenesis of a variety of autoimmune diseases such as psoriasis.iii  Neutralisation of IL-17A by ixekizumab inhibits these pro-inflammatory actions.iii

Ixekizumab is administered by subcutaneous injection, either via auto-injector or prefilled syringe.iii

In UNCOVER-1 the results show that when treated every two weeks with ixekizumab for 12 weeks following a starting dose, approximately 9 of 10 patients achieved a PASI 75 score.iiiIn both UNCOVER-2 and UNCOVER-3 etanercept was used as an active comparator. The results show that approximately 9 of 10 patients treated with ixekizumab every two weeks achieved a PASI 75 score at week 12, and approximately 8 of 10 patients achieved clear or almost clear skin as defined by sPGA 0 or 1 respectively.iii,

Numerous secondary end points were also collected from the UNCOVER series of trials, including higher levels of clearance, (PASI 90, 100 and sPGA 0). The impact of psoriasis on patient's lives was assessed using patient reported outcome measures, including the DLQI. Across UNCOVER-1 and UNCOVER 2&3, 35.3 percent and 39 percent of patients, respectively achieved PASI 100 (clear skin) after 12 weeks of treatment with ixekizumab.iii

The approved dosing regimen for ixekizumab is a 160-mg starting dose by subcutaneous injection (two 80-mg injections) at Week 0, followed by 80 mg (one injection) every two weeks through 12 weeks, then maintenance dosing of 80 mg (one injection) every four weeks.iii

Lilly received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on February 25, 2016.v

Safety information

The very common (≥1/10 patients) adverse events in clinical trials were injection site reactions and upper respiratory tract infections (most frequently nasopharyngitis).iii

About the UNCOVER Studies

The UNCOVER-1, UNCOVER-2 and UNCOVER-3 studies are double-blind, multicentre, Phase III studies evaluating more than 3,800 patients with moderate-to-severe plaque psoriasis from 21 countries.iii

All three studies evaluated the safety and efficacy of different dosing regimens of ixekizumab (80 mg every two or four weeks, following a 160-mg starting dose) compared to placebo after 12 weeks.iii

·       UNCOVER-2 and UNCOVER-3 included an additional comparator arm in which patients received etanercept (50 mg twice a week) for 12 weeks.iv

·       UNCOVER-1, UNCOVER-2 and UNCOVER-3 also evaluated response rates with ixekizumab during the maintenance period through 60 weeks, with UNCOVER-1 and UNCOVER-2 employing a randomized withdrawal design.iii,iv

·       In these studies, the co-primary efficacy endpoints at 12 weeks were Psoriasis Area Severity Index (PASI) 75 and static Physician’s Global Assessment (sPGA) 0 or 1.iiiPASI measures the extent and severity of psoriasis by assessing average redness, thickness and scaliness of skin lesions (each graded on a zero to four scale), weighted by the body surface area of involved skin, while the sPGA is the physician’s assessment of severity of a patient’s psoriasis lesions overall at a specific point in time.vi Both assessment tools (PASI and sPGA) are in line with CHMP guidelines to assess the effectiveness of treatments for psoriasis.vii

 

News Articles [94 Associated News Articles listed on BioPortfolio]

Human medicines European public assessment report (EPAR): Remsima, infliximab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Psoriasis,Crohn Disease,Arthritis, Rheumatoid, Date of authorisation: 10/09/2013, Revision: 14, Status: Authori

Human medicines European public assessment report (EPAR): Remsima, infliximab, Arthritis, Psoriatic,Spondylitis, Ankylosing,Colitis, Ulcerative,Psoriasis,Crohn Disease,Arthritis, Rheumatoid, Date of a...

T Cell Specific Surface Glycoprotein CD28 TP44 or CD28 Pipeline Review, H2 2018 [Report Updated: 13112018] Prices from USD $3500

T Cell Specific Surface Glycoprotein CD28 TP44 or CD28 Pipeline Review, H2 2018SummaryT Cell Specific Surface Glycoprotein CD28 TP44 or CD28 CD28 is a proteins expressed on T cells. It costimulates ...

Human medicines European public assessment report (EPAR): Otezla, apremilast, Arthritis, Psoriatic,Psoriasis, Date of authorisation: 15/01/2015, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Otezla, apremilast, Arthritis, Psoriatic,Psoriasis, Date of authorisation: 15/01/2015, Revision: 6, Status: Authorised

Global Autoimmune Drugs Market 2018-2022 | Market Dominance by TNF- α Inhibitors to Boost Growth | Technavio

The global autoimmune drugs market is expected to post a CAGR of over 8% during the period 2018-2022, according to the latest market research report by Technavio. This press...

Competitor Landscape: Psoriasis [Report Updated: 31102018] Prices from USD $6400

Competitor Landscape: PsoriasisSummarySociable Pharma's Treatment Landscape' contains evaluations of ongoing development activities within the Psoriasis PsO market, analysis of current potential futu...

Competitor Landscape: Spondyloarthritis [Report Updated: 30112018] Prices from USD $6400

Competitor Landscape: SpondyloarthritisSummarySociable Pharma's Treatment Landscape' contains evaluations of ongoing development activities within the spondyloarthritis SpA market, analysis of current...

Competitor Landscape: Psoriasis [Report Updated: 31102018] Prices from USD $5440

Competitor Landscape: PsoriasisSummarySociable Pharma's Treatment Landscape' contains evaluations of ongoing development activities within the Psoriasis PsO market, analysis of current potential futu...

Competitor Landscape: Spondyloarthritis [Report Updated: 30112018] Prices from USD $5440

Competitor Landscape: SpondyloarthritisSummarySociable Pharma's Treatment Landscape' contains evaluations of ongoing development activities within the spondyloarthritis SpA market, analysis of current...

Akaal Pharma Pty Ltd Announces Licensing Agreement for its First-in-Class, Topical Spingosine-1-Phosphate-1 (S1P1) Receptor Modulator for Atopic Dermatitis and Psoriasis

Akaal Pharma Pty Limited (Akaal Pharma) today announced that it has entered into a licensing agreement for Akaal Pharma’s First-in-Class, topical Spingosine-1-Phosphate-1 (S1P1)...

Human medicines European public assessment report (EPAR): Humira, adalimumab, Spondylitis, Ankylosing,Arthritis, Juvenile Rheumatoid,Uveitis,Colitis, Ulcerative,Psoriasis,Arthritis, Psoriatic,Crohn Disease,Arthritis, Rheumatoid, Date of authorisation: 07/

Human medicines European public assessment report (EPAR): Humira, adalimumab, Spondylitis, Ankylosing,Arthritis, Juvenile Rheumatoid,Uveitis,Colitis, Ulcerative,Psoriasis,Arthritis, Psoriatic,Crohn Di...

Companies [27 Associated Companies listed on BioPortfolio]

FotoFinder Systems

Founded in 1991 the German company is specialized in skin cancer diagnostics by means of Automated Total Body Mapping, digital dermoscopy, in hair diagnostics, psoriasis documenta...

Akaal Pharma Pty Limited

Akaal Pharma is a private clinical-stage, Australian biotech company focused on advancing the clinical development of its internally discovered topical and oral small molecule dru...

Luma Therapeutics

Based in Silicon Valley, Luma Therapeutics is a privately held medical technology company committed to developing innovative and convenient therapies for the millions of people ar...

LEO Pharma A/S

LEO Pharma is a globally, leading pharmaceutical company within Dermatology and Critical Care. We maintain a strong focus on developing, manufacturing and marketing safe and efficacious drugs for tre...

Ra Medical Systems, Inc.

Ra Medical Systems was founded in 2002 and is a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of dermatolog...

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion d...

Arrien Pharmaceuticals

Arrien Pharmaceuticals is a targeted therapeutics drug discovery and development company. Arrien applies its proprietary fragment-based FIELDS drug discovery technology to targ...

Tiziana Life Sciences plc

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The C...

Santalis Pharmaceuticals, Inc.

Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and a...

Ziarco Pharma Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, ...

Clinical Trials [713 Associated Clinical Trials listed on BioPortfolio]

This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream

This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating the efficacy, safety and convenience of...

Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.

Single center, randomized, double-blind, placebo-controlled clinical study to assess the safety and tolerability of PBF-1650 in order to obtain the Maximum Tolerated Dose (MTD).

Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling

The purpose of this study is to collect skin biopsies and non-invasive microneedle device samples from participants with mild chronic plaque psoriasis vulgaris to use for transcriptomics p...

Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment

This study will assess differences in inflammatory proteins, lipoprotein composition, cholesterol efflux and HDL-proteome in moderate-to-severe pediatric psoriasis who at baseline begin sy...

A Study to Test BI 655130 in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

To evaluate efficacy, safety, and tolerability of BI 655130 compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe i...

An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis

This Phase 3 multicenter, randomized, placebo-controlled, double-blind study is designed to evaluate the efficacy and safety of apremilast in subjects with moderate to severe genital psori...

A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life.

This is a Phase 4, multi-center, randomized, placebo-controlled, double-blind study of the impact of apremilast on quality of life, efficacy, and safety in subjects with manifestations of ...

APACHE Cohort (A Psoriatic Arthritis CoHort)

Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease, belonging to the wide spectrum of spondyloarthritis, but with the particularity to be associated with personal psoria...

Genetic Analysis of Pediatric Psoriasis

This study will ascertain approximately 150 subjects, which will include pediatric psoriasis patients diagnosed before age 12, parents not affected by psoriasis, and if a family history is...

Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis

Phase 1 study in 2 stages with 2 expansion cohorts. The first stage is a single ascending dose (SAD) study of APVO210 in healthy volunteers. The second stage is a multiple ascending dose (...

PubMed Articles [346 Associated PubMed Articles listed on BioPortfolio]

The ultrasonographic study of the nail reveals differences in patients affected by inflammatory and degenerative conditions.

The nail unit is a subject of interest in several diseases, often involving different medical fields. Even if few data are available for psoriasis and psoriatic arthritis, no data regarding ultrasonog...

Mechanical stretch exacerbates psoriasis by stimulating keratinocyte proliferation and cytokine production.

Psoriasis is a chronic inflammatory autoimmune skin disease that often occurs in rubbed areas undergoing a strong mechanical stretch, such as the elbows and knees. However, the pathologic role of mech...

Atopic dermatitis is an IL-13 dominant disease with greater molecular heterogeneity compared to psoriasis.

Atopic dermatitis (AD) affects up to 20% of children and adults worldwide. To gain a deeper understanding of the pathophysiology of AD, we conducted a large-scale transcriptomic study of AD with deepl...

Reflectance Confocal Microscopy Features of Plaque Psoriasis Overlap With Horizontal Histopathological Sections: A Case Series.

Reflectance confocal microscopy (RCM) displays horizontal, en face tissue sections of the epidermis and upper dermis, and interpretation of its features is classically based on the comparison with ver...

Crossed looks on the dermatologist's position and the patient's preoccupations as to psoriasis and pregnancy: preliminary results of the PREGNAN-PSO study.

While some information on psoriasis impact on pregnancy is available, very little is known on the preoccupations of women afflicted by the disease or on the dermatologists' (D) positioning as to psori...

HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa.

Hidradenitis suppurativa (HS) is a chronic, relapsing, inflammatory skin disease characterized by painful inflamed nodules, recurrent abscesses, and fistulas located in apocrine gland-bearing body sit...

Analyzing cysteine site neighbors in proteins to reveal dimethyl fumarate targets.

This work proposes a novel approach by which to consistently classify cysteine sites in proteins in terms of their reactivity toward dimethyl fumarate (DMF) and fumarate. Dimethyl fumarate-based drug ...

Thyroid function in psoriasis.

Psoriasis has been associated with other autoimmune diseases, e.g. inflammatory bowel disease and autoimmune thyroid disease. These diseases may share genetic susceptibility loci and autoimmune mechan...

Factors associated with onychomycosis in nail psoriasis: a multicenter study in Pakistan.

Treatment of psoriatic nail disease is challenging, and dystrophic psoriatic nails can get secondarily infected with fungi.

IL-23- and Imiquimod-Induced Models of Experimental Psoriasis in Mice.

Genome-wide association studies have found that polymorphisms in genes for IL-23 and its receptor are important in psoriasis, and blocking IL-23 is an effective therapy in the disease. The use of Alda...

Medical and Biotech [MESH] Definitions

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.

A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.

An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.

A humanized monoclonal antibody that binds to IL-12 and IL-23 and is used as a DERMATOLOGIC AGENT in the treatment of patients with plaque PSORIASIS who have not responded to other therapies.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Cytokine
Cytokines include chemokines, lymphokines, and monokines. Cells of the immune system communicate with one another by releasing and responding to chemical messengers called cytokines. These proteins are secreted by immune cells and act on other cells to...

Cytokine Tumour Necrosis Factor (TNF)
TNF is a compound that is classified as a cytokine which plays a central role in the cellular mechanisms of apoptosis or cell death. However, there are a number of different kinds of TNF, just under twenty, but the family of molecules have very similar a...